Analgesic nephropathy epidemiology and demographics

Jump to navigation Jump to search

Analgesic nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Analgesic nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Treatment

Medical Therapy

Future or Investigational Therapies

Case Studies

Case #1

Analgesic nephropathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Analgesic nephropathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Analgesic nephropathy epidemiology and demographics

CDC on Analgesic nephropathy epidemiology and demographics

Analgesic nephropathy epidemiology and demographics in the news

Blogs on Analgesic nephropathy epidemiology and demographics

Directions to Hospitals Treating Analgesic nephropathy

Risk calculators and risk factors for Analgesic nephropathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]

Overview

There is insufficient evidence about the incidence, prevalence and racial predilection of analgesic nephropathy. However, the classic analgesic nephropathy is disappearing after the removal of phenacetin from the markets over 30 years ago. Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain. Studies suggest that analgesic nephropathy is more conman in females than males.

Epidemiology and Demographics

Incidence

  • There is insufficient evidence about the incidence of analgesic nephropathy.
  • However, the classic analgesic nephropathy is disappearing after the removal of phenacetin from the markets over 30 years ago.[1]

Prevalence

  • There is insufficient evidence about the prevalence of analgesic nephropathy.
  • However, the classic analgesic nephropathy is disappearing after the removal of phenacetin from the markets over 30 years ago.[1]

Age

Most patients with analgesic nephropathy have been reported to be middle age or older with a history of chronic pain.[2]  

Race

There is insufficient evidence that suggests racial predilection in analgesic nephropathy.

Gender

Studies suggest that analgesic nephropathy is more conman in females than males. [3]

References

  1. 1.0 1.1 Mihatsch MJ, Khanlari B, Brunner FP (2006). "Obituary to analgesic nephropathy--an autopsy study". Nephrol Dial Transplant. 21 (11): 3139–45. doi:10.1093/ndt/gfl390. PMID 16891638.
  2. Yaxley J (2016). "Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence". Int J Risk Saf Med. 28 (4): 189–196. doi:10.3233/JRS-170735. PMID 28582877.
  3. Gault MH, Wilson DR (1978). "Analgesic nephropathy in Canada: clinical syndrome, management, and outcome". Kidney Int. 13 (1): 58–63. doi:10.1038/ki.1978.8. PMID 713269.

Template:WH Template:WS